LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

8.880 -0.100 (-1.11%)

Official Closing Price Updated: 4:15 PM EDT, May 1, 2026 Add to My Watchlist

Price and Volume

Volume	852,335
Open	8.960
Bid (Size)	8.810 (100)
Ask (Size)	9.000 (300)
Prev. Close	8.980
Today's Range	8.740 - 9.120
52wk Range	8.250 - 50.40
Shares Outstanding	58,102,949
Dividend Yield	162.39%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

April 20, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week ↗

March 27, 2026

It failed to meet expectations for its final quarter of 2025.

Via The Motley Fool

Performance

YTD	-44.5%	-44.5%
1 Month	-3.0%	-3.0%
3 Month	-50.1%	-50.1%
6 Month	-70.8%	-70.8%
1 Year	-68.9%	-68.9%

More News

Why Lenz Therapeutics Stock Crashed Today ↗

March 24, 2026

Via The Motley Fool

LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch ↗

March 24, 2026

Via Chartmill

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

March 24, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings ↗

March 23, 2026

Via Benzinga

LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

March 17, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

March 10, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Present at Upcoming Investor Conferences

February 23, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

January 14, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

January 07, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

January 05, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

December 01, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Present at Upcoming Investor Conferences

November 25, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q3 2025 Revenue Beat and Progress on VIZZ Launch ↗

November 05, 2025

Via Chartmill

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 05, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

October 29, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

September 30, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation

September 27, 2025

Via MarketMinute

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?

Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?

LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?

The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market

What is the current price of LENZ Therapeutics, Inc. - Common Stock?

The current price of LENZ Therapeutics, Inc. - Common Stock is 8.880

When was LENZ Therapeutics, Inc. - Common Stock last traded?

The last trade of LENZ Therapeutics, Inc. - Common Stock was at 05/01/26 04:15 PM ET

What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?

The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 515.95M

How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?

LENZ Therapeutics, Inc. - Common Stock has 516M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.